Chardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They currently have a $1.25 target price on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 70.77% from the company’s previous close.

Several other brokerages have also recently weighed in on MCRB. The Goldman Sachs Group dropped their price objective on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.00.

Seres Therapeutics Stock Performance

NASDAQ:MCRB traded down $0.05 on Thursday, hitting $0.73. 998,438 shares of the stock were exchanged, compared to its average volume of 3,414,403. The stock has a market capitalization of $127.45 million, a price-to-earnings ratio of -3.18 and a beta of 2.19. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The company’s 50-day moving average price is $0.79 and its 200 day moving average price is $0.83.

Institutional Trading of Seres Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC increased its stake in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC increased its stake in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares in the last quarter. Avantax Advisory Services Inc. increased its stake in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares in the last quarter. Jane Street Group LLC increased its stake in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 37,866 shares in the last quarter. Finally, State Street Corp increased its stake in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.